| 期 |
栏目 |
标题 |
文件 |
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| 卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| 卷 25, 编号 4 (2023) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
| 卷 26, 编号 2 (2024) |
Articles |
Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study |
(Rus)
|
| 卷 26, 编号 2 (2024) |
Articles |
Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study |
(Rus)
|
